10:18:50 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



Oncolytics Biotech Inc (2)
Symbol ONC
Shares Issued 25,010,089
Close 2019-12-09 C$ 1.46
Market Cap C$ 36,514,730
Recent Sedar Documents

Oncolytics's pelareorep subject of poster presentation

2019-12-09 08:03 ET - News Release

Dr. Rita Laeufle reports

ONCOLYTICS BIOTECH(R) ANNOUNCES POSITIVE MULTIPLE MYELOMA DATA PRESENTED AT THE 61ST ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY

A poster presentation was given over the weekend highlighting preclinical and clinical results of combining Oncolytics Biotech Inc.'s pelareorep with the proteasome inhibitor carfilzomib in the treatment of multiple myeloma. The presentation was given on Saturday, Dec. 7, as part of the 2019 American Society of Hematology annual meeting and exhibition.

The poster, titled, "Carfilzomib Impairs the Innate Antiviral Immune Response and promotes cytotoxic T-cell Expansion in Oncolytic Virus Treated Multiple Myeloma Patients" describes synergies between proteasome inhibitors and pelareorep concerning immune cell changes and response in myeloma patients.

"These findings demonstrate that pelareorep, in combination with carfilzomib, infects multiple myeloma cells, thereby providing a strong scientific rationale regarding immune cell changes," said Dr. Rita Laeufle, chief medical officer at Oncolytics Biotech. "The combination of carfilzomib and pelareorep promotes expansion of killer T-cells in patients on an ongoing phase 1b study and how it may lead to tumour response when pelareorep is combined with proteasome inhibitors. We are confident that pelareorep could add significant clinical value to the treatment of multiple myeloma patients with the combination of these agents. Our first data in patients from an ongoing study has been very encouraging and further data will be presented at subsequent clinical conferences."

Key data and conclusions

  • Demonstrated that pelareorep treatment selectively infected multiple myeloma cells and not normal bone marrow cells;
  • Carfilzomib enhances reovirus entry, infection and killing of multiple myeloma cells;
  • Reovirus significantly increases the frequency and activation of certain killer T-cells, and increases the anti-tumour activity of immune cells in multiple myeloma;
  • Data supports that the combination of pelareorep, and carfilzomib potentiates the expansion of CD8-plus killer T-cells.

The poster presentation was authored by Dr. Flavia Pichiorri, associate professor in the Judy and Bernard Briskin Center for Multiple Myeloma Research within the Hematologic Malignancies and Stem Cell Transplantation Institute at the city of Hope, et al. The poster can be found on the posters and publications page of Oncolytics's website.

Title:  "Carfilzomib Impairs the Innate Antiviral Immune Response and promotes cytotoxic T-cell Expansion in Oncolytic Virus Treated Multiple Myeloma Patients"

Number:  1816

Presenter:  Dr. Flavia Pichiorri

Program:  oral and poster abstracts

Session:  652 myeloma: pathophysiology and preclinical studies, excluding therapy: poster I

About Pelareorep

Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumours and hematological malignancies. The compound induces selective tumour lysis and promotes an inflamed tumour phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumour lysis and promotes an inflamed tumour phenotype -- turning cold tumours hot -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.